Primary Cells Market – Top Players and Growth Strategies

According to research report the pimary cells market is expected to reach USD 1,107.3 million by 2023 from USD 736.4 million in 2018, at a CAGR of 8.5%. Factors driving the growth of this market include the increasing adoption of primary cell over cell lines, increasing R&D activities for the development of new cancer therapies, and increasing collaborations & acquisitions.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=32854960

The primary cells market is consolidated in nature, with a few number of players offering variety of products. The key players in the market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics (US), PromoCell (Germany), ZenBio (US), STEMCELL Technologies (US), AllCells (US), American Type Culture Collection (US), and Axol Biosciences (UK).

Most companies in the primary cells market adopted expansions and acquisitions as the key business growth strategy. These strategies accounted for the largest share of the overall growth strategies mapped from 2015 to 2018.

Thermo Fisher Scientific (US)

Thermo Fisher Scientific held the leading position in the primary cells market in 2017. Due to its well-established product portfolio, the company maintained its leading position in the primary cells market. The company adopted acquisitions as a key strategy in order to strengthen its position as well as expand its product portfolio. For instance, in 2016, the company acquired MTI-GlobalStem (US) in order to increase and expand its primary cells portfolio.

 Merck KGaA (Germany)

In 2017, Merck KGaA ranked second in the primary cells market. The company offers a wide range of products in this market. The company adopted both inorganic growth strategies in order to increase its dominance in this market. The company is highly focused on the Asia Pacific region and investments in countries like China, India, and South Korea. For instance, the company acquired Sigma-Aldrich (US) in 2015, in order to increase and expand its primary cells portfolio.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=32854960

Lonza (Switzerland)

Lonza is engaged in providing chemical and biotechnology ingredients and custom manufacturing services to pharmaceutical, healthcare, and life science industries. The company operates through two divisions, namely, Specialty Ingredients and Pharma & Biotech. Through its Pharma & Biotech segment, the company offers human and animal primary cells. The company adopted product launches as a key strategy in order to strengthen its position as well as expand its product portfolio. For instance, in 2018, Lonza expanded its primary cells portfolio and added hepatic stellate cells, Kupffer cells, and liver-derived endothelial cells to its hepatocytes portfolio.

Bioinformatics Market worth $13.50 billion in 2023

According to research report the Bioinformatics Market is projected to reach USD 13.50 billion in 2023 from USD 7.73 billion in 2018, at CAGR of 14.5%. Growing demand for nucleic acid and protein sequencing, initiatives from government and private organizations, growing applications of bioinformatics, and the increasing number of collaborations between companies and research institutes are the major factors driving the growth of the market.

Based on product and service, the bioinformatics platforms segment is projected to grow at the highest CAGR in the market during the forecast period

On the basis of product & service, the market is broadly segmented into knowledge management tools, bioinformatics platforms, and services. The bioinformatics platform segment is projected to grow at the highest CAGR during the forecast period. This high growth can be attributed to the increasing usage of different bioinformatics platforms in various genomic and proteomics applications. Additionally, there is an increase in the use of bioinformatics platforms in drug discovery and development, which also contributes to the growth of the market.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=39

Based on applications, the genomics segment is estimated to account for the largest share of the market in 2018

On the basis of applications, the global bioinformatics market is divided into genomics, chemoinformatics and drug design, proteomics, transcriptomics, and metabolomics. In 2018, the genomics segment is expected to account for the largest share of the bioinformatics market. The rising application of genomics in personalized and preventive medicine is positively affecting market growth.

Based on sector, the medical biotechnology segment is estimated to account for the largest share of the market in 2018

On the basis of sector, the global bioinformatics market is divided into medical biotechnology, academics, animal biotechnology, agricultural biotechnology, environmental biotechnology, and forensic biotechnology. The medical biotechnology is again subdivided into drug discovery & development, clinical diagnostics & precision medicine, reproductive health. In 2018, the medical biotechnology segment is estimated to account for the largest share of the bioinformatics market. The rising adoption of bioinformatics tools in pharmaceutical and clinical applications is driving market growth.

North America is expected to dominate the market in 2018

Among the four geographic regions, North America is expected to account for the largest share of the bioinformatics market in 2018, followed by Europe, APAC, and the RoW. The large share of North America is attributed to the steady funding from the government and private sector for life sciences research and bioinformatics.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=39

Market Players

The bioinformatics market is highly competitive due to the presence of a large number of players. Few of the major companies in bioinformatics market are Thermo Fisher Scientific (US), Illumina Inc (US), Agilent Technologies (US), QIAGEN (Netherlands), BGI (China), Wuxi NextCODE (China), Eurofins Scientific (Luxembourg), Waters Corporation (US), Sophia Genetics (Switzerland), Partek (US), and DNASTAR (US).

Defibrillators Market worth 10.88 Billion USD by 2022

According to the new market research report  Debrillators Market  is projected to reach USD 10.88 Billion by 2022 Billion in 2017, growing at a CAGR of 3.1%. providing public access defibrillation, and rising numbers of training & awareness programs across the globe are driving the growth of this market.

Speak to Analyst:  https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=549

By product, the implantable cardioverter defibrillators segment is expected to hold the largest share of the market in 2017

The ICDs are implantable defibrillators (ICDs) and external defibrillators (ICDs) and external defibrillators. The ICDs are segmented into implantable defibrillators. T-ICDs segment is further classified into single-chamber ICDs, dual-chamber ICDs, and cardiac resynchronization therapy (CRT-Ds). The external classifieds segment is further classified into a manual classified as an external defibrillator. Cardioverter defibrillators (WCDs). The ICDs segment is expected to account for the largest share of the global defibrillators market in 2017.Factors such as development of technologically advanced devices with extended longevity, rapid growth in the number of implant procedures, and increasing adoption of cardiac therapy therapies (CRT-Ds) and S-ICD systems this segment.

By end user, the  public access markets segment is expected to be the fastest growing segment in the forecast period

Pre-hospital care settings; home care settings; and alternate care facilities. The public access markets segment is is expected to grow at the end user, the defibrillators market is segmented into hospitals, clinics, and cardiac centers; Growth in this segment is attributed to the development of advanced AEDs, rising cases of sudden cardiac arrest, and out-of-hospital settings, and increasing numbers of public access delibriation programs across the globe.

Download Brochure:  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=549

North America is expected to dominate the market in 2017

Geographically, the defibrillators market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to account for the largest share of the market in 2017, followed by Europe. The largest share of North America can primacy be attributed to the rising population population, increasing incidence of cardiovascular disease, and continuous technological advancements & product innovations in the region.

The key players in the defibrillators market include Medtronic (Ireland), St. Jude Medical (US), Boston Scientific (US), Koninklijke Philips NV (Netherlands), ZOLL Medical (US), BIOTRONIK (Germany), Physio-Control (US) ), Cardiac Science (US), LivaNova (UK), Nihon Kohden (Japan), SCHILLER (Switzerland), Mindray Medical (China), Mediana (South Korea), METRAX (Germany), and METsis (Turkey).

Contrast Media Market Key Players and Global Forecast 2022

According to research report the global contrast media market is expected to reach USD 5.53 Billion by 2022 from an estimated USD 4.57 Billion in 2017, growing at a CAGR of 3.9% during the forecast period. Growth in the contrast media market can primarily be attributed to factors such as increasing number of approvals for contrast agents and growing number of public & private diagnostic centers. The increasing number of research and funding activities for research of contrast agents and their applications provides immense opportunities for players in the contrast media market

The key players in this market are continuously striving to gain product approvals to secure larger shares and expand their existing product portfolios. The overall market was dominated by Bayer HealthCare (Germany), GE Healthcare (U.S.), Guerbet Group (France), Bracco Imaging S.p.A (Italy), Lantheus Medical Imaging (U.S.), nanoPET Pharma GmbH (Germany), CMC Contrast AB (Sweden), Daiichi Sankyo (Japan), and Subhra Pharma Private Limited (India).

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=911

Bayer HealthCare (Germany) was the leading player in the contrast media/contrast agents market with a share of ~24% in 2015. The company continuously strives to strengthen its market position in various geographies by focusing on getting approvals for contrast media products across the world. Gadovist injection, a gadolinium-based contrast agent by Bayer, has received FDA approval in the U.S. and Japan. Gadovist is the first FDA-approved contrast agent for pediatric patients less than 2 years of age, including term neonates. The company’s major share in the market can be attributed to its broad product portfolio, several years of experience, extensive distribution channel, and various growth strategies, such as product approvals, collaborations, and expansions. The company focuses on developing innovative healthcare products with a positive cost-benefit ratio.

Bayer HealthCare invested 5.8%, 5.5%, and 5.5% of its total healthcare revenue in 2013, 2014, and 2015, respectively, in R&D activities. The company has gained a major share in the contrast media/contrast agents market on account of its comprehensive product portfolio, wide geographical reach; focus on organic growth strategies, as well as constant focus on research and developmental activities.

GE Healthcare (U.S.) held the second-largest share of ~21% in the contrast media/contrast agents market in 2015. The firm has a strong customer base in approximately 175 countries, primarily operating in North America, Europe, the Pacific Basin, the Americas, and the Middle East & Africa. Some subsidiaries of the firm include GE Healthcare USA Holdings, Inc., GE Healthcare Ltd. (Japan), GE Healthcare Biosciences AB (U.S.), and GE Healthcare AS (Norway). GE Healthcare received the Norwegian Medicines Agencys (NOMA) approval for SONAZOID, a contrast agent used in ultrasound imaging of focal liver lesions. However, with competition in the market and the entry of new companies, it is necessary for GE to innovate continuously in order to keep its technology at the forefront and maintain its position in the market. The company’s robust product portfolio, large number of subsidiaries, focus on customers, and new product launches have also helped expand its share in the contrast media/contrast agents market.

Sample of the report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=911

Players operating in the contrast media/contrast agents market adopted strategies such as product approvals, which was the most-preferred strategy (43.6% of the total strategic developments in the market during 2013 to 2016). The key players that have adopted this strategy include Bayer HealthCare (Germany), GE Healthcare (U.S.), Guerbet Group (France), Bracco Imaging S.p.A (Italy), Spago Nanomedicine AB (Sweden), and CMC Contrast AB (Sweden).

Clinical Microbiology Market Future Growth Forecast to 2022

According to research report Clinical Microbiology Market is expected to reach USD 4.95 billion by 2023 from USD 3.63 billion in 2018, at a CAGR of 6.4%.

The major factors driving the growth of the clinical microbiology market include technological advancements in the field of infectious disease diagnostics, rising incidence and prevalence of infectious diseases and growing outbreak of epidemics, and the increased funding and public-private investments for the development of novel products for infectious disease diagnosis.

Pharmaceutical applications are expected to dominate the microbiology testing market in 2018

The microbiology testing market is segmented on the basis of applications into pharmaceutical, clinical, food testing, energy, chemical and material manufacturing, and environmental applications. The pharmaceutical applications segment is expected to dominate the overall microbial testing market in 2018 due to the presence of well-established and globally accepted regulations that govern the evaluation of microbial contamination during pharmaceutical manufacturing and raw material sourcing processes.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=219135367

Laboratory instruments are projected to hold the largest share of the clinical microbiology instruments market in 2018

The clinical microbiology market is segmented on the basis of products into instruments (laboratory instruments and microbiology analyzers) and reagents (pathogen-specific kits and general reagents). The laboratory instruments products segment is expected to command the largest share of the global clinical microbiology instruments market in 2018 due to factors such as continuous technological advancements in the field of microbiology testing instruments and the focus on laboratory automation (coupled with the integration of robotics with conventional microbiology instruments).

Respiratory diseases are expected to be the largest diseases area in clinical microbiology market in 2018

On the basis of disease area, the clinical microbiology market is segmented into respiratory diseases, bloodstream infections (BSIs), gastrointestinal (GI) diseases, sexually transmitted diseases (STDs), urinary tract infections (UTIs), periodontal diseases, and other diseases (including cardiovascular disease, central nervous system infections, connective tissue & joint diseases, and skin diseases). The respiratory disease segment is estimated to account for largest share of the global clinical microbiology market owing to the large patient population suffering from respiratory diseases, rising prevalence of target respiratory diseases (including TB, asthma, COPD, and bronchitis) across developing countries, and increasing number of epidemic outbreaks of respiratory infections.

North America is expected to dominate the clinical microbiology market in 2018

Geographically, the market is segmented into North America (the US and Canada), Europe (Germany, the UK, France, and the Rest of Europe), Asia Pacific (Japan, China, India, and the Rest of APAC), and the Rest of the World (Latin America, and the Middle East and Africa). North America is expected to account for the largest share of the global clinical microbiology market in 2018 due to easy accessibility and high adoption of advanced diagnostic techniques, technological advancements in microbial testing techniques, rising geriatric population, and growing public-private funding to support microbiology-based research in the region.

Download Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=219135367

The major players operating in the microbiology testing/clinical microbiology market include bioMérieux SA (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Bruker Corporation (US), Hologic, Inc. (US), QIAGEN N.V. (The Netherlands), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Shimadzu Corporation (Japan), 3M Company (US), and Neogen Corporation (US), among others.

Liquid Biopsy Market by Cancer Type and Product Global Forecast 2022

According to research report the global liquid biopsy market is projected to reach USD 2,047.9 million by 2022

According to research report the global liquid biopsy market is projected to reach USD 2,047.9 million by 2022 from USD 715.7 million in 2017, at a CAGR of 23.4%. The factors driving the growth of this market are the increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.
Speak to analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=13966350 
Cancers in areas such as the bones, brain, pancreas, or other organs were hard to access with liquid biopsy. However, post 2014, the sensitivity of liquid biopsy tests has improved greatly. Presently, ultra-sensitive methods such as digital PCR, NGS, and microfluidics are designed to capture CTCs and ctDNA—key biomarkers for cancer. These methods permit the analysis of ctDNA, providing physicians with important biomarker information to take effective therapeutic decisions in almost all cancer areas. The development of technologically advanced liquid biopsy products is aiding the growth of the market.
In this report, the market is segmented on the basis of product, circulating biomarker, clinical application, application, end user, and region. On the basis of product, the global liquid biopsy market is segmented into assays kits, instruments, and services. The assay kits segment is expected to account for the largest share in the liquid biopsy market in 2017. Increase in demand for liquid biopsy tests, increasing basic research and commercial applications of liquid biopsy, and the need for reliable and specific assays are expected to drive the liquid biopsy assay kits market. It is also the fastest-growing segment in the products market during the forecast period.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 
Based on circulating biomarkers the market is categorised into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. The extracellular vesicles is the fastest-growing segment in the circulating biomarkers market during the forecast period. This is due to the growing interest in EV research from biofluids such as the blood and urine of cancer patients as a means of disease diagnosis and therapeutic monitoring. 
Based on clinical application, the liquid biopsy market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The early cancer screening segment is expected to be the fastest-growing segment in the clinical application market during the forecast period. The factor driving the growth of this segment is the ability to detect populations at high risk of cancer using liquid biopsy during early stages of cancer through early screening methods. 
Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications (which includes reproductive health and organ transplant diagnostics). The non-cancer application segment is expected to be the fastest-growing segment in the application market during the forecast period. This is due to growing NIPT applications in gender identification, identification of trisomies, and other genetic abnormalities which include monosomy X and microdeletions. NIPT is also replacing amniocentesis in high-risk pregnancies.
Based on end user, the liquid biopsy market is segmented into reference laboratories, hospitals and physician laboratories, academic and research centers, and other end users (public health laboratories, pathology laboratories, and small molecular laboratories). Reference laboratories form the fastest-growing end-user segment of the liquid biopsy market. The large share of this segment is attributed to the increasing volume of liquid biopsy test samples outsourced to reference laboratories. 
Geographically, the liquid biopsy market in the APAC region is expected to register the highest CAGR during the forecast period. Rising disposable incomes in the middle-class populations have led to an increase in healthcare spending in India and China. This, along with infrastructural developments and rising penetration of cutting-edge diagnostic technologies in these countries, is a major factor providing significant growth opportunities for manufacturers and distributors of liquid biopsy products in this region.